Overview

Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes

Status:
Completed

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to address the safety issue of whether, in patients with newly-diagnosed diabetes who still make some insulin, proinsulin peptide therapy adversely affects the rate of damage to the insulin making cells.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Cardiff University

Collaborators:

Diabetes Vaccine Development Centre
Juvenile Diabetes Research Foundation

Treatments:

Insulin
Insulin, Globin Zinc